---
title: "Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295528778.md"
description: "Kardigan, Inc. reported a net loss of $116.2M and diluted EPS of $(4.61) for Q2 2026, widening from the prior year's loss. The company recorded no revenue as it invests in late-stage clinical programs for danicamtiv, ataciguat, and tonlamarsen, with topline data expected in H1 2027. Operational costs rose due to R&D scale-up and M&A integration efforts."
datetime: "2026-08-11T11:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295528778.md)
  - [en](https://longbridge.com/en/news/295528778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295528778.md)
generator: "portal-rs"
---

# Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary

Kardigan, Inc. reported a net loss of $116.2M for the second quarter of 2026 and diluted loss per share of $(4.61). The company recorded no revenue for the three- or six-month periods ended June 30, 2026, as it continues to invest heavily in late-stage clinical programs and platform integration.

**Financial Highlights**

-   Revenue: No revenue reported for the three- or six-month periods ended June 30, 2026 or 2025.
-   Net income: Net loss $116.2M for 2Q 2026, compared with net loss $57.4M in 2Q 2025 (approximately a $58.8M increase in loss year over year).
-   Diluted EPS: Net loss per share, basic and diluted $(4.61) for 2Q 2026, versus $(4.64) in 2Q 2025.

**Business Highlights**

-   Clinical program progress: Advanced three late-stage programs—danicamtiv, ataciguat and tonlamarsen—with ongoing Phase trials and topline data expected in H1 2027.
-   Operational scale-up: Increased R&D activity, headcount growth and greater use of external CROs/CMOs have driven higher program spending during the quarter.
-   Platform and M&A integration: Continued integration of the Prolaio platform with amended milestones; the platform is being used for trial patient management and analytics.
-   Commercial positioning: Management is preparing commercialization planning for targeted precision cardiovascular indications and pursuing clear regulatory pathways pending trial outcomes and approvals.

Original SEC Filing: Kardigan, Inc. \[ KARD \] - 10-Q - Aug. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KARD.US](https://longbridge.com/en/quote/KARD.US.md)

## Related News & Research

- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Apple declares Q3 2026 distribution of R$ 0.05 per unit, payable Aug. 19](https://longbridge.com/en/news/296137926.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Jacktel to webcast Q2, H1 2026 results](https://longbridge.com/en/news/296198778.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**